絞り込み

18453

広告

Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.

著者 McNeish IA , Strickland S , Holden L , Rustin GJ , Foskett M , Seckl MJ , Newlands ES
J Clin Oncol.2002 Apr 1 ; 20(7):1838-44.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Medical Oncology, Trophoblastic Tumour Screening and Treatment Center, Charing Cross Hospital, London, United Kingdom.

スターを付ける スターを付ける     (33view , 0users)
We have simplified the treatment of gestational trophoblastic disease (GTD) in order to reduce the number of patients exposed to potentially carcinogenic chemotherapy. Patients who score 0 to 8 on the Charing Cross scoring system are classified as low-risk and receive methotrexate (MTX) and folinic acid (FA), whereas those who score higher than 8 are classified as high-risk and receive the etoposide, methotrexate, and dactinomycin (EMA)/cyclophosphamide and vincristine (CO) regimen.
PMID: 11919242 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード